(Q24202090)

5

Jonathan C Craig

0 references

Giovanni Strippoli

6

Giovanni FM Strippoli

0 references

Celine Foote

3

Celine V Foote

0 references

Maria E. Craig

4

Maria E Craig

0 references

author name string

Jicheng Lv

Cochrane Database of Systematic Reviews

1

0 references

publication date

12 December 2012

0 references

published in

0 references

cites work

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Appropriate Blood Pressure Control in NIDDM (ABCD) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Lowering blood pressure reduces renal events in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Ramipril lowered cardiovascular risk, but vitamin E did not

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Blood-pressure reduction and cardiovascular risk in HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The effects of losartan and fosinopril in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

ACE-I and ARBs in early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Barriers to clinical research participation in a diabetes randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effect of telmisartan on renal outcomes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Long-term lisinopril therapy reduces exercise-induced albuminuria in normoalbuminuric normotensive IDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The CARI guidelines. Prevention and management of chronic kidney disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Antihypertensive agents for preventing diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Antihypertensive agents for preventing diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Prevention of microalbuminuria in patients with type 2 diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Factors Determining the Blood Pressure Response to Enalapril and Nifedipine in Hypertension Associated With NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

The Effects of Enalapril and Nifedipine on Carbohydrate and Lipid Metabolism in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Renal and retinal effects of enalapril and losartan in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in ID

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004136.PUB3

7 January 2021

10.1002/14651858.CD004136.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23235603

1 reference

Consolidated OpenCitations Corpus – April 2017